Shares of enGene Holdings Inc. (ENGN) are down over 65% from their 52-week high of $18.40, recorded in March of this year, and trade around $6.
This clinical-stage biotechnology company is focused on developing genetic medicines based on its proprietary dually derived chitosan, or "DDX", gene delivery platform to improve the lives of patients suffering from bladder cancer. Its lead investigational product is Detalimogene voraplasmid, a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com